Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALK Avanz
- Development stage
- Phase 3
- Lead developer
- ALK Abelló
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
ALK Avanz is an allergen extract developed by ALK-Abelló for subcutaneous allergen-specific immunotherapy (SCIT). It is used to treat seasonal allergic rhinoconjunctivitis, particularly that induced by grass pollen allergens. The drug functions as an immunomodulator, aiming to desensitize the immune system to specific allergens and reduce allergic reactions.
- Brand names
- AvanzAVANZ Phleum pratense
- Other names
- Grass pollen allergy immunotherapy low dose - ALK-AbelloGrass pollen allergy vaccine - ALK-Abello
Beyond the preview
Go deeper on ALK Avanz.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALK Avanz.